๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Optimized PGT-M Strategy for Patients With No Proband
NCT06722313De Novo Mutation, Preimplantation Genetic Testing, Without Proband
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
5
Shanghai
2023-01-01
Recruiting
Correlation Between Parameters and Prognosis of Cervical Single Open-door Surgery
NCT05767164Cervical Spinal Stenosis
Xijing Hospital
Not applicable
500
Xi'an
2023-01-01
Recruiting
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NCT05926726Hepatocellular Carcinoma
RenJi Hospital
Not applicable
12
Shanghai
2023-01-01
Recruiting
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT05603559Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1
30
Beijing
2023-01-01
Active, closed
Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma
NCT07459127NUT Carcinoma
Three Gorges Hospital of Chongqing University
Observational
150
Chongqing
2023-01-01
Recruiting
The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and Prognosis
NCT06624488Cardiac Arrest (CA), Brain Injuries, Acute
Tang Ziren
Observational
30
Beijing
2023-01-01
Recruiting
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
NCT06802718Acute Myeloid Leukemia
Peking University People's Hospital
Phase 3
96
Beijing
2023-01-01
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
NCT06277024Overall Response Rate
Fujian Medical University
Not applicable
50
Fuzhou
2023-01-01
Recruiting
AI-Based Ultrasound Prediction of Pregnancy Outcomes in Placental-Related Fetal Growth Restriction (MVM-FGR): A Prospective Cohort Study
NCT07473739Fetal Growth Restriction (FGR)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
300
Shanghai
2023-01-01
Recruiting
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
NCT06033287Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors, Subsequent Treatment
Hunan Cancer Hospital
Observational
300
Changsha
2023-01-01
Recruiting
To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)
NCT06772454Lung Cancer Squamous Cell, COPD
Guangzhou Institute of Respiratory Disease
Observational
60
Guangzhou
2023-01-01
Recruiting
Leflunomide for Henoch-Schonlein Purpura
NCT05937880Henoch-Schonlein Purpura
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
36
Guangzhou
2023-01-01
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
Fudan University
Phase 2
55
Shanghai
2023-01-01
Recruiting
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion
NCT05589207Carcinoma, Renal Cell, Tumor Thrombus, Neoplasm Invasiveness, Inferior Vena Cava Interruption
Peking University Third Hospital
Observational
232
Beijing
2023-01-01
By invitation
Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct
NCT06924996Acute Basilar Artery Occlusion, Posterior Circulation Large Infarct
Feng Gao
Observational
500
Beijing
2023-01-01
Recruiting
Daratumumab for Patients With Light Chain Amyloidosis
NCT06376214Light Chain (AL) Amyloidosis
Nanjing University School of Medicine
Not applicable
100
Nanjing
2023-01-01
Recruiting
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
NCT05503875Immunoclassification, Psoriasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2023-01-01
By invitation
Melatonin and Perinatal Outcomes in MVM-Related Fetal Growth Restriction (MIMVMFGR)
NCT07549295Fetal Growth Restriction (FGR)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
240
Shanghai
2023-01-01
Not yet open
Prediction of Development and Rupture Risk for Intracranial Unruptured Aneurysms
NCT05576727Intracranial Aneurysm
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2023-01-01
Recruiting
A Prospective Study on the Treatment of cLM Based on ICG Imaging
NCT06275022Lymphatic Malformation
Nanjing Children's Hospital
Not applicable
110
Nanjing
2023-01-01
Active, closed
Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
NCT07335029Cerebrovascular Disease, Intracranial Aneurysm, Intracranial Arterial Dissection
Beijing Neurosurgical Institute
Observational
208
Beijing
2023-01-01
Recruiting
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
NCT05777824Head and Neck Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
84
Beijin
2023-01-01
Recruiting
AI-Driven Prediction of Dialysis Outcome With EHR
NCT06791447Dialysis Patients
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Beijing
2023-01-01
Recruiting
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
NCT05672043Medulloblastoma, Central Nervous System Tumor, Pediatric, Ependymoma, Germ Cell Tumor
Beijing Tiantan Hospital
Observational
400
Beijing
2023-01-01
Active, closed
3D-CT-Based Prediction of Difficult Laryngoscopy in Infants With Pierre Robin Sequence
NCT07257276Pierre Robin Sequence (PRS), Difficult Laryngoscopy, Airway Management
Nanjing Children's Hospital
Observational
294
Nanjing
2023-01-01
Recruiting
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
NCT06248697Solid Tumor
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
16
Shanghai
2023-01-01
Not yet open
Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds
NCT05589454Acute Ischemic Stroke, Cerebral Microbleeds
Sichuan Provincial People's Hospital
Phase 4
344
Chongqing, Chengdu, Ya'an, Zigong
2023-01
Not yet open
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT05590572Osteosarcoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
148
Beijing, Jinan, Shanghai
2023-01
Not yet open
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT05505461Adenocarcinoma of Esophagogastric Junction
Peking University People's Hospital
Phase 2
26
Beijing
2023-01
Recruiting
Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
NCT07370077Lung Cancer
Chen KeZhong
Observational
1,800
Beijing
2022-12-31
Active, closed
Application of Multitask Deep Learning Model in Grading the Severity of Spinal Facet Joint Degeneration
NCT05635006Facet Joints; Degeneration ; Deep Learning ;Artificial Intelligence
Hai Lv
Observational
1,132
Zhuhai
2022-12-31
Active, closed
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
NCT05765032Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
220
Tianjin
2022-12-30
Recruiting
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
NCT05562024B7-H3-positive Relapsed/ Refractory Neuroblastoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
24
Jinan, Tianjin
2022-12-30
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
NCT05837806Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
21
Tianjin
2022-12-30
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Not yet open
A Clinical Trial of the Transcatheter Aortic Valve Implantation System With a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients With Severe Aortic Stenosis
NCT05673525Aortic Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
131
Beijing
2022-12-30
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche
Phase 3
1,290
Guangzhou, Zhanjiang, Zunyi, Lianyungang, Beijing, Changchun, Changsha, Chengdu
2022-12-29
Recruiting
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
NCT05622409Primary Malignant Brain Tumors
National Health Research Institutes, Taiwan
Observational
250
2022-12-29
Recruiting
Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury
NCT05623722Sepsis, Acute Gastrointestinal Injury, Organ Dysfunction Syndrome
Jing Cai, MD
Not applicable
116
Guangzhou
2022-12-29
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Recruiting
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
NCT06258408Advanced Solid Tumor
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Recruiting
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
NCT05687851Locally Advanced Cervical Cancer
Chongqing University Cancer Hospital
Phase 2
33
Chongqing
2022-12-29
Recruiting
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
NCT05556603Cancer
Ruijin Hospital
Observational
7,062
Shanghai
2022-12-28
Recruiting
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
NCT05587543Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1
24
Shanghai
2022-12-28
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Recruiting
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
NCT05745623Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
70
Guangzhou
2022-12-27
Recruiting
Phase 1 Trial of KH617
NCT05667194Advanced Solid Tumors
Sichuan Honghe Biotechnology Co., Ltd.
Phase 1
45
Beijing
2022-12-26
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in SheMountain
NCT05667935Alzheimer Disease, Dementia, Neurodegenerative Diseases, Cognitive Impairment
Ruijin Hospital
Observational
2,000
Shanghai
2022-12-26
Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106Carcinoma, Renal Cell Carcinoma, RCC, Kidney Neoplasms
Jinling Hospital, China
Observational
450
Nanjing
2022-12-26
Recruiting
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
NCT05584267Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
140
Changsha
2022-12-25
Active, closed
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526Alzheimer Disease
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Recruiting
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
NCT05512351Oligodendroglioma
Henan Provincial People's Hospital
Phase 2
80
Zhengzhou
2022-12-23
Recruiting
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
NCT05682755Leukemia, Myeloid, Acute
Sichuan University
Phase 1/2
77
Chengdu
2022-12-22
Recruiting
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT05757336Gallbladder Cancer, Initially Unresectable, the First Line Treatment
Lu Wang, MD, PhD
Phase 2
50
Shanghai
2022-12-22
Recruiting
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
NCT05862103Acute Myocardial Infarction, Adverse Event
Yu Bo
Observational
15,000
Beijing, Guangzhou, Nanning, Shijiazhuang, Daqing, Zhengzhou, Nanjing, Nanchang
2022-12-21
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
AstraZeneca
Phase 1
167
Beijing, Chongqing, Guangzhou, Wuhan
2022-12-21
Recruiting
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
NCT05653453Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Active, closed
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
NCT05621499Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2022-12-20
Recruiting
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
NCT05749289SSTR Positive Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
400
Beijing
2022-12-20
Active, closed
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
NCT05507112Locally Advanced Rectal Cancer
Peking Union Medical College Hospital
Phase 2
100
Beijing
2022-12-20
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Recruiting
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
NCT05475678Breast Cancer, Triple Negative Breast Cancer, Camrelizumab
Zhenzhen Liu
Phase 2
369
Zhengzhou
2022-12-20
Not yet open
Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
NCT05532969Astrocytoma
Henan Provincial People's Hospital
Observational
60
Zhengzhou
2022-12-20
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Recruiting
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
NCT05638594Breast Cancer
Shengjing Hospital
Phase 2
236
Shenyang
2022-12-20
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Active, closed
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Phase 3
20
Chongqing, Guangzhou, Chengdu, Beijing
2022-12-19
Active, closed
A Study Assessing Repathaยฎ in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Not yet open
Study on Gene Evolution in Glioma Under Stress Therapy
NCT05512325Genetic Change
Henan Provincial People's Hospital
Observational
100
Zhengzhou
2022-12-17
Recruiting
Hainan Community Cognition Cohort
NCT06686186Cognitive Impairment, Dementia, Age Problems
Hainan Medical College
Observational
2,000
Haikou
2022-12-16
Recruiting
Phase โ…ก Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Venous Leg
NCT05319106Venous Leg Ulcer
ShiCang Yu
Not applicable
76
Chongqing
2022-12-15
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Recruiting
Thrombus Imaging and Treatment Analytics in Neurology
NCT05663281Thrombus, Brain, Thrombosis
Chinese PLA General Hospital
Observational
100
Beijing
2022-12-15
Recruiting
A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers
NCT05592886Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Advanced Adenoma
Chinese University of Hong Kong
Not applicable
649
Hohhot
2022-12-15
Active, closed
Effect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair
NCT05603468Tendinopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
387
Hangzhou
2022-12-15
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Not yet open
Sex Hormone Overdose and Misuse in Chinese Transgender and Gender Non-conforming Population
NCT05583058Gender Incongruence, Gender Dysphoria
Xiamen University
Observational
260
Xiamen
2022-12-15
Active, closed
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
NCT05513573Nasopharyngeal Carcinoma by AJCC V8 Stage
Shanghai Henlius Biotech
Phase 2
75
Guanzhou
2022-12-14
Active, closed
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
NCT05469737Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 2/3
230
Wuhan
2022-12-14
Active, closed
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
NCT05683353SARS-CoV-2 Infection, Hematologic Malignancy
Peking University First Hospital
Observational
60
Beijing
2022-12-14
Recruiting
Long-term Follow-up Study of BHC001 for TDT
NCT06314529Thalassemia, Beta
Bioray Laboratories
Observational
6
Nanning, Changsha
2022-12-14
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Changsha
2022-12-14
Active, closed
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500Lupus Erythematosus, Systemic
Viatris Innovation GmbH
Phase 3
470
2022-12-13
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 3
324
รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-12-13
Recruiting
Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
NCT05814952X-linked Retinoschisis
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2022-12-13
Active, closed
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
NCT06417476Rectal Neoplasms
Pei-Rong Ding
Phase 2
66
Guangzhou
2022-12-12
Recruiting
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
NCT05555888Early Low Rectal Cancer
Fudan University
Phase 2
34
Shanghai
2022-12-12
Active, closed
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT05481476Pancreatic Neoplasms
Sun Yat-sen University
Phase 2
32
Guangzhou
2022-12-12
Recruiting
Myopia Control Combined PBM With Myopic Defocus Lens in Children
NCT05756959Myopia, Progressive
Beijing Airdoc Technology Co., Ltd.
Not applicable
304
Xuzhou
2022-12-12
Not yet open
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
NCT05502991Glioblastoma
Henan Provincial People's Hospital
Phase 2
60
Zhengzhou
2022-12-11
Recruiting
Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy in R/R NHL
NCT05554939Non Hodgkin's Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2022-12-11
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Active, closed
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05263583High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Cothera Bioscience, Inc
Phase 2
14
Beijing, Guangzhou, Henan, Pudong, Tianjin, Wuhan
2022-12-09
Active, closed
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (ฮฑ)-Thalassemia
NCT05664737Anemia
Bristol-Myers Squibb
Phase 2
189
Guangzhou, Foshan, Maoming Shi, Shenzhen Shi, Liuzhou, Nanning, Haikou, Kunming
2022-12-09
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Recruiting
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05827796Pancreatic Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2
70
Shanghai
2022-12-08
Rows per page Showing 15901–16000 of 19052
Previous 158 159 160 161 162 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=160

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.